Arrowhead Pharmaceuticals, Inc. (ARWR) Lifted to Sell at ValuEngine

ValuEngine upgraded shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) from a strong sell rating to a sell rating in a research note published on Monday morning.

Several other analysts have also weighed in on the stock. Cantor Fitzgerald reaffirmed a hold rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, September 25th. William Blair raised shares of Arrowhead Pharmaceuticals from a market perform rating to an outperform rating in a report on Monday, September 18th. Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. Jefferies Group LLC reaffirmed a hold rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Friday, August 4th. Finally, Piper Jaffray Companies reaffirmed a hold rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $2.00.

Arrowhead Pharmaceuticals (ARWR) opened at 4.40 on Monday. Arrowhead Pharmaceuticals has a one year low of $1.20 and a one year high of $7.48. The company’s market capitalization is $329.00 million. The company has a 50-day moving average price of $3.17 and a 200-day moving average price of $2.04.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The company had revenue of $9.34 million during the quarter, compared to analyst estimates of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. Equities research analysts anticipate that Arrowhead Pharmaceuticals will post ($0.42) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/10/05/arrowhead-pharmaceuticals-inc-arwr-lifted-to-sell-at-valuengine.html.

Institutional investors have recently modified their holdings of the stock. UBS Asset Management Americas Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 414.7% in the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 53,500 shares in the last quarter. Virtu KCG Holdings LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 115.6% in the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 53,215 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 287.9% in the first quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 74,776 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 18.0% in the fourth quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock valued at $175,000 after purchasing an additional 17,201 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of Arrowhead Pharmaceuticals by 144.8% in the first quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock valued at $278,000 after purchasing an additional 88,933 shares in the last quarter. 20.61% of the stock is owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply